Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Find starter accounts offering high interest and learn how to compare introductory yields and account features quickly.
25,613 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Jim Cramer argues Meta's AI model shift delivered a roughly $100 per share move, illustrating why big tech remains ha...
A cooler June CPI print sparked a risk-on bid in semiconductors, with AMD surging and Intel climbing as investors bet...
A joint U.S.-Russian crew has arrived at the ISS, signaling continued cooperation in orbit even as global tensions pe...
Microsoft stock has slipped in 2026, but a strong earnings report could ignite a rebound. This guide breaks down what...
Palo Alto Networks’ stock has surged in recent weeks as AI-powered cyber spending accelerates, prompting bullish targ...
As lawmakers race toward two July floor windows, the CLARITY Act stands as the key to how digital assets are classifi...
A lone receipt sparked a high-stakes investigation into a months-long fraud ring. This article explains how self-chec...
Alphabet's Gemini delays raise questions about AI leadership and stock resilience. This guide analyzes what the lag m...
Housing equity for Americans aged 62 and older hit a new high in the first quarter of 2026, driven by rising home val...
Wingstop topped Q4 expectations, delivering a key earnings beat while expanding its restaurant base. The dual story: ...
A prominent billionaire asserts the market is underestimating how far the Federal Reserve may go with rate cuts. This...